Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases
Open accessThe DOI matches its Crossref record; 132 of the 136 references it cites were found in a registry or an index.
Abstract
Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world. Until recently, there were no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signaling pathway implications in fibrosis could design new strategies for therapeutic benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stiff matrices activate ILK-STAT3 and YAP/TAZ signaling, enhancing RORgt expression and promoting Th17 differentiation.”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [86]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“DNA demethylation, generally linked with gene silencing, has recently been identified as a strategy in the regulation of IL-17-dependent fibrosis.”
Unique features of long non-coding RNA biogenesis and function
Quinn, J. J., & Chang, H. Y. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.10 · Cited by 3,672 · cited 1×
“This would be essential to identify not only new therapies but also predictive biomarkers for the diagnosis of fibrotic diseases, such as many autoimmune diseases.”
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“IL-17A and F are the closest members, with 50% homology, followed by IL-17B (29%), IL-17D (25%), and IL-17C (23%); IL-17E displays the lowest degree of sequence conservation (16%), implicating that IL-17E is the most dissimilar protein [19,20].”
Long non-coding RNAs: definitions, functions, challenges and recommendations
Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L.-L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., et al. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00566-8 · Cited by 2,356 · cited 1×
“…and effectiveness of therapies targeted against IL-17 subtypes and to clarify the multiple molecular pathways in which they appear to carry out their regulatory activity, it will be necessary to elucidate the immunological and genetic circumstances under which IL-17 becomes pro-fibrotic.”
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 2×
“Many studies have revealed that miRNAs and lncRNAs are key regulators of the development of fibrotic processes, often correlated with autoimmune conditions.”
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971 · cited 1×
“These data confirmed that cytokines drive the acute and chronic inflammatory responses that culminate in fibrosis activation [8].”
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 1×
“Interestingly, in pathological disorders that are based on inflammatory processes, altered repair mechanisms can lead to the formation of fibrotic tissue upon wound healing [4], which may be responsible for aberrant tissue repair [1].”
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 1×
“In liver fibrosis, IL-17, operating in synergy with IL-1 β , IL-6, and IL-23, continues the inflammatory process by promoting transforming growth factor-β (TGF β ) expression in hepatic stellate cells [48,49].”
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 1×
“IL-17A and IL-17F link to a dimeric IL17RA/RC system; IL-17B and IL-17E link to a dimeric 17RA/RB system; and IL-17C links to the IL17RA/RE complex [26].”
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443 · cited 4×
“IL-17RA and IL-17RC, acting through the binding of the SEFIR domain with the ubiquitin ligase Act1, activate the TRAF6/TAK1/NF-κ B pathway and the TRAF6/TAK1/MAPK/AP1 pathway [28].”
Influential
Cited by
Smith, J. A., & Rai, V. (2024) · Biomedicines · doi:10.3390/biomedicines12091939 · Cited by 109
“…in the proliferation and migration of epidermal keratinocytes [103], fibroblast proliferation, activation, function (ECM production), senescence, and differentiation [104], and stimulates smooth muscle cell migration involving MMP-9, p38 MAPK and ERK1/2-dependent NF-κ B, and AP-1 activation [105].”
BackgroundDonniacuo, A., Mauro, A., Cardamone, C., Basile, A., Manzo, P., Dimitrov, J., Cammarota, A. L., Marzullo, L., Triggiani, M., Turco, M. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188921 · Cited by 44
“One of the mechanisms through which IL-17 contributes to the progression of SS is the induction of epithelial– mesenchymal transition (EMT) in glandular epithelial cells, which leads to fibrosis and functional tissue loss [121].”
Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
Rolski, F., & Ma̧czewski, M. (2025) · Pharmaceuticals · doi:10.3390/ph18030313 · Cited by 37
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
IL-17 is Associated with Disease Severity and Targetable Inflammatory Processes in Heart Failure
Baumhove, L., van Essen, B. J., Dokter, M. M., Zijlstra, S. N., Deiman, F. E., Laman, J. D., Lang, C. C., Verstappen, G. M. P. J., van Veldhuisen, D. J., van der Meer, P., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14968 · Cited by 21
Metadata
- Authors
- Sisto, M., & Lisi, S.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Sisto, Margherita
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-12-27
- Volume
- 13
- Issue
- 1
- Pages
- 164
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10780256
- OpenAlex
- W4390265558
- Cited by
- 22
- References
- 136
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 3 · 2023: 1
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- IL-17, fibrotic diseases, fibrosis, antifibrotic therapy, chronic inflammation, epigenetic regulation, IL-17 signaling, organ failure, autoimmune disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. https://app.cochat.ai/papers/10.3390/jcm13010164
- The paper
- Sisto, M., & Lisi, S. (2023). Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13010164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.